Health Canada Approves Ozempic to Reduce Heart Attack and Stroke Risk
Health Canada expands Ozempic approval to include reducing the risk of heart attacks and strokes in adults with type 2 diabetes and heart or kidney disease.
Generic Ozempic: Canada to See Significant Price Drops
Struggling with high medication costs? Generic Ozempic is coming to Canada in 2026. Learn how prices could drop from $400 to around $100.
Ozempic, Wegovy and Mounjaro Are Changing Our Food Choices
Appetite-suppressing GLP-1 medications may be changing the way Canadians eat – Smaller appetites and healthier choices are impacting restaurants and the food supply sector in significant ways.
Ozempic, Wegovy Lawsuits Raise Alarms Over Rare Vision Loss Risk
U.S. lawsuits link Ozempic and similar drugs to rare vision loss. Learn the risks of semaglutide medications and what Canadians should watch for.
Ozempic Now Approved to Treat Kidney Disease in Patients with Type 2 Diabetes
A major international study called The FLOW trial has resulted in approval for Ozempic from Health Canada to help treat CKD in people with type 2 diabetes.
Ozempic and GLP-1 Drugs – Surprising New Health Benefits
From diabetes care to potential benefits for heart health, Alzheimer’s, and more, GLP-1 drugs like Ozempic are reshaping medicine.
Taking Ozempic? Better Understand The Long Term Impact
Weight loss drugs like Ozempic are changing lives but as with all medications, they can come with side effects. Learn more about the risks scientists are discovering as their use becomes more widespread.
Fitness In 2026 Looks VERY Different
Ditch the solo grind. In 2026, social wellness and "third space" gyms are fighting the loneliness epidemic through pickleball and city-wide run clubs.
New Study Warns of Rapid Weight Regain When Quitting Weight Loss Drugs
New research shows stopping weight loss medication leads to rapid regain, with many returning to their original weight in less than two years.
Health Canada Authorizes First GLP-1 Pill to Reduce Heart Attack and Stroke Risk
Health Canada authorizes RYBELSUS® as the first oral GLP-1 to reduce heart attack and stroke risk in adults with type 2 diabetes.
Top Neurologist Shares Promising New Insights In Alzheimer’s Research; Video Interview
Watch this Interview with Doctor Howard Chertkow, one of Canada's leading neurologists, and learn more about new insights into Alzheimer's prevention and care.
Ashwagandha 101: The Adaptogen Everyone’s Popping—Should You Join the Hype?
Ashwagandha is everywhere right now. From stress relief to sex drive—see which claims check out, and which should raise red flags.